To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

Combined treatment with h… - University of Gothenburg, Sweden Till startsida
To content Read more about how we use cookies on

Combined treatment with histamine dihydrochloride, interleukin-2 and interferon-alpha in patients with metastatic melanoma

Journal article
Authors P. Lindner
Magnus Rizell
Jan Mattsson
Kristoffer Hellstrand
Peter Naredi
Published in Anticancer Res
Volume 24
Issue 3b
Pages 1837-42
ISSN 0250-7005 (Print)
Publication year 2004
Published at Institute of Surgical Sciences, Department of Surgery
Institute of Laboratory Medicine, Dept of Clinical Virology
Pages 1837-42
Language en
Keywords Adult, Aged, Antineoplastic Combined Chemotherapy Protocols/adverse effects/ therapeutic use, Female, Histamine/administration & dosage/adverse effects/blood/pharmacokinetics, Humans, Immunotherapy/ methods, Interferon Alfa-2b/administration & dosage/adverse effects, Interleukin-2/administration & dosage/adverse effects, Male, Melanoma/blood/secondary/ therapy, Middle Aged
Subject categories Medical and Health Sciences


BACKGROUND: Histamine inhibits phagocyte-derived production of reactive oxygen species and improves the anti-tumour efficiency of interleukin-2 (IL-2) and interferon-alpha (IFN-alpha) in vitro and in tumour-bearing animals. PATIENTS AND METHODS: In a phase-II study, twenty-seven patients with stage IV melanoma received subcutanous injections of histamine dihydrochloride (histamine) 1.0 mg and IL-2 2.4 MIU/m2 twice daily (BID) days 1-5 and 8-12. IFN-alpha 3 MIU once daily was administered throughout a cycle (days 1-28; n=14). Alternatively, bolus doses of IL-2 10 MIU/m2 BID days 1 and 2 and histamine days 1-28 (n=13) were administered. The aim was to study efficiency (survival and tumour response), toxicity and histamine pharmacokinetics. RESULTS: The median survival time was 11.3 (2.5-45) months. One patient achieved a complete response and 3 patients had partial responses. The compounds were safely self-administered with low toxicity. Plasma histamine concentrations significantly increased after an injection of histamine over 10 minutes (3 +/- 1 vs. 63 +/- 27 nmol/l). CONCLUSION: Histamine, IL-2 and IFN-alpha treatment is safe, well-tolerated and tumour responses were observed. The putative efficiency of histamine as an adjunct to cytokine therapy in metastatic melanoma needs to be confirmed in later randomized trials.

Page Manager: Webmaster|Last update: 9/11/2012

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?